iBio Inc. (NYSEAMERICAN:IBIO) has announced that it has been selected by IBM Watson Health to use the IBM Clinical Development solution for 18 months.
ICD platform to help iBio in advancing the development of COVID-19 vaccine
Recently IBM Watson Health started offering the ICD solution to trial sponsor entities that are eligible. This is part of the company’s efforts to boost support for the medical community in addressing COVID-19. So far, there has been a lot of interest in IBM Watson Health’s solution form several hospitals, contract research companies, academic institutions, and sponsors.
Tom Isett, the CEO and Co-Chairman of iBio, stated that they were delighted and appreciated the confidence of IBM Watson Health. He added that this recognizes the company’s potential in developing a COVID-19 vaccine form among the several organizations that had applied to use the ICD solution. Isett added that the technology will help support the efficient and rapid conducting of clinical trials of the company’s COVID-19 vaccine candidates.
The CEO indicated that the technology will also complement iBio’s FastPharming System’s quality, core speed as well as scale-up benefits in the development of therapeutics and vaccines. Isett added that through strategic collaboration like the one with IBM, the company is now better positioned with the right technology, tools, and capital to facilitate development efforts of a COVID-19 vaccine.
iBio expects results from preclinical studies in Q3
Currently, iBio is anticipating data from preclinical immunization trials for its two coronavirus vaccine candidates. The two vaccines IBIO 200 and IBIO-201 are being evaluated at the Texas A&M University System laboratories, and results will be available in Q3.
Mary Varghese Presti, the VP Life Sciences IBM Watson Health, stated that the COVID-19 pandemic is a global health crisis. As a result, there is an increasing agency to develop effective and safe treatments considering the infection rates have continued to escalate. She added that the company was committed to leverage the ICD solution to help in accelerating timelines for clinical studies for COVID-19 vaccine candidates.
